Here's Why TransMedics (TMDX) is a Strong Growth Stock

Core Insights - Zacks Premium provides various tools to enhance stock market investment confidence and effectiveness [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, and Price/Sales [4] - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] - The Momentum Score helps investors capitalize on price or earnings trends, utilizing one-week price changes and monthly earnings estimate changes [6] - The VGM Score combines all three Style Scores, serving as a crucial indicator alongside the Zacks Rank for identifying stocks with strong value, growth, and momentum [7] Zacks Rank and Performance - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to aid in portfolio creation [8] - Stocks rated 1 (Strong Buy) have achieved an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [9] - There are over 800 top-rated stocks available, making it essential to utilize Style Scores for effective selection [10] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [11] - Stocks with lower ranks but high Style Scores may still pose risks if they have downward-trending earnings forecasts [12] Company Spotlight: TransMedics Group - TransMedics Group (TMDX) is a medical technology company focused on organ transplant therapy, currently rated 3 (Hold) with a VGM Score of A [13] - TMDX is projected to experience a year-over-year earnings growth of 129.7% for the current fiscal year, making it appealing for growth investors [13][14] - The Zacks Consensus Estimate for TMDX has risen by $0.42 to $2.32 per share, with an average earnings surprise of +45.4% [14]